Boston Scientific Co. (NYSE:BSX) Shares Acquired by Baird Financial Group Inc.

Baird Financial Group Inc. increased its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 12.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 227,298 shares of the medical equipment provider’s stock after purchasing an additional 25,732 shares during the quarter. Baird Financial Group Inc.’s holdings in Boston Scientific were worth $20,302,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. TFC Financial Management Inc. raised its stake in shares of Boston Scientific by 308.8% in the 4th quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 210 shares during the period. West Oak Capital LLC acquired a new stake in Boston Scientific in the 4th quarter valued at approximately $29,000. Valley National Advisers Inc. raised its position in Boston Scientific by 262.4% in the fourth quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 286 shares during the period. Fairway Wealth LLC acquired a new position in Boston Scientific during the fourth quarter worth $36,000. Finally, Global Trust Asset Management LLC boosted its position in shares of Boston Scientific by 64.5% during the fourth quarter. Global Trust Asset Management LLC now owns 436 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 171 shares during the period. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Trading Down 0.0 %

NYSE BSX opened at $104.22 on Wednesday. The firm’s fifty day moving average price is $98.71 and its 200 day moving average price is $95.66. Boston Scientific Co. has a 12 month low of $71.88 and a 12 month high of $107.17. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. The company has a market capitalization of $154.15 billion, a price-to-earnings ratio of 83.38, a price-to-earnings-growth ratio of 2.79 and a beta of 0.68.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.08. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. The company had revenue of $4.66 billion for the quarter, compared to analyst estimates of $4.57 billion. During the same quarter last year, the company posted $0.56 earnings per share. The business’s quarterly revenue was up 20.9% compared to the same quarter last year. On average, sell-side analysts expect that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, EVP John Bradley Sorenson sold 4,572 shares of the company’s stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $104.54, for a total value of $477,956.88. Following the completion of the sale, the executive vice president now directly owns 18,705 shares of the company’s stock, valued at approximately $1,955,420.70. This represents a 19.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Vance R. Brown sold 4,826 shares of the firm’s stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $95.09, for a total value of $458,904.34. Following the transaction, the senior vice president now directly owns 36,193 shares in the company, valued at approximately $3,441,592.37. This represents a 11.77 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 307,025 shares of company stock valued at $31,742,060 over the last quarter. Company insiders own 0.50% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Citigroup increased their target price on Boston Scientific from $107.00 to $122.00 and gave the stock a “buy” rating in a research note on Thursday, February 6th. Morgan Stanley raised their price objective on shares of Boston Scientific from $100.00 to $120.00 and gave the company an “overweight” rating in a research note on Thursday, February 6th. Deutsche Bank Aktiengesellschaft upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 price objective for the company in a report on Friday, January 10th. Raymond James increased their target price on shares of Boston Scientific from $119.00 to $122.00 and gave the stock a “strong-buy” rating in a report on Thursday, February 6th. Finally, BTIG Research restated a “buy” rating and issued a $124.00 price target on shares of Boston Scientific in a research note on Wednesday, April 23rd. Twenty-three analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Boston Scientific currently has an average rating of “Buy” and an average target price of $114.52.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.